-
Oct.292018NEWS
HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S.
HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innova..
-
Oct.012018NEWS
HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China
HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND i..
-
Aug.142018NEWS
HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion
HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaroun..
-
Jul.112018NEWS
HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant
HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch..
-
Jun.252018NEWS
HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization(WHO)
HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World He..
-
May.292018NEWS
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036(a new drug for dry eye syndrome) in the U.S.
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036..